4 November 2020
Appendix 2A
30 October 2020
Appendix 2A
30 October 2020
Quarterly Cashflow and Activities Report
29 October 2020
Completion of Placement and SPP raises $48.9M in total
21 October 2020
Starpharma receives $5.7M R&D tax incentive refund
20 October 2020
Shareholder Update October 2020
19 October 2020
Notice of Annual General Meeting/Proxy Form
9 October 2020
Change in substantial holding
8 October 2020
Change in substantial holding
8 October 2020
Change in substantial holding
8 October 2020
Change in substantial holding
7 October 2020
Share Purchase Plan offer document
6 October 2020
Appendix 2A
6 October 2020
Cleansing Notice
5 October 2020
Change in Director's Interest Notice - R Thomas
5 October 2020
Change in Director's Interest Notice - J Fairley
30 September 2020
Investor Presentation
30 September 2020
Starpharma completes oversubscribed A$45M placement
30 September 2020
Proposed issue of Securities
28 September 2020
Trading halt

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.